Founded in Sweden in 2015, Cyxone runs an international network of experts in research, development, and manufacturing. Their goal is to create an innovative and effective drug portfolio that reduces side effects and slows down the disease development of autoimmune disorders. Their current portfolio includes Rabeximod, in clinical phase II program for rheumatoid arthritis, and T20K, in clinical phase I for multiple sclerosis. In the future, they plan to use their cyclotide technology to develop new structures that may benefit patients with other diseases.